Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 3/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | GLP1R | P43220 | 8/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 2/20 | 0.35 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.35 |
| ▸ | CHRNG | P07510 | 1/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.35 |
| ▸ | CHRND | Q07001 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22702633 | 0.92 | TRPV1 (0.38) | FURINHTTCHRNA1CHRNGCHRNB1 | |
| SCHEMBL22746601 | 0.91 | MMP3 (0.43) | FURINMMP3MMP2HTTNPY1R | |
| SCHEMBL25830868 | 0.90 | FURIN (0.36) | FURINGLP1RHTTNPY1RNPY4R | |
| SCHEMBL22138371 | 0.90 | FURIN (0.44) | FURINGLP1RHTTCHRNA1CHRNG | |
| SCHEMBL24591729 | 0.89 | GLP1R (0.39) | FURINGLP1RFAPCHRNA1CHRNG | |
| SCHEMBL25826704 | 0.88 | SIRT2 (0.37) | FURINHTTFAPNPY1RNPY4R | |
| SCHEMBL25726157 | 0.87 | CHRND (0.41) | FURINHTTFAPCHRNA1CHRNG | |
| SCHEMBL25726153 | 0.87 | CHRND (0.41) | FURINHTTFAPCHRNA1CHRNG | |
| SCHEMBL24829575 | 0.87 | SIRT1 (0.41) | FURINHTTFAPCHRNA1CHRNG | |
| SCHEMBL22138449 | 0.87 | SIRT1 (0.41) | FURINHTTFAPCHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | Regeneran Pharmaceuticals, Inc. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20200368361-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200368361-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | FURIN 794/4885MMP3 3893/4885MMP2 1894/4885 |
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | GLUL, TGM2, GLS | FURIN 826/4885MMP3 2609/4885MMP2 2241/4885 |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | ASGR1, CUTA, SRPRA | FURIN 794/4885MMP3 3893/4885MMP2 1894/4885 |
| US-11701427-B2 | Diels-alder conjugation methods | GLUL, TGM2, GLS | FURIN 826/4885MMP3 2609/4885MMP2 2241/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | FURIN 2044/4885MMP3 3825/4885MMP2 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.